Bulletin
Investor Alert

Alkermes PLC

NAS: ALKS

GO
/marketstate/country/us

After Hours

/zigman2/quotes/205084517/composite

$

16.74

Change

0.00 0.00%

Volume

Volume 91,742

Sep 25, 2020, 4:29 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/205084517/composite

Today's close

$ 16.53

$ 16.74

Change

+0.21 +1.27%

Day low

Day high

$16.44

$16.80

Open
Open: 16.54

52 week low

52 week high

$11.98

$21.88

Open

Market cap

$2.63B

Average volume

1.32M

P/E ratio

N/A

Rev. per Employee

$475,771

EPS

-0.80

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/alks

MarketWatch News on ALKS

  1. Alkermes downgraded to neutral from buy at BofA Securities

    11:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  2. Alkermes stock price target cut to $20 from $31 at BofA Securities

    11:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  3. Alkermes downgraded to neutral from overweight at J.P. Morgan

    8:51 a.m. Feb. 14, 2020

    - Tomi Kilgore

  4. Alkermes stock price target cut to $21 from $25 at J.P. Morgan

    8:52 a.m. Feb. 14, 2020

    - Tomi Kilgore

  5. FDA told Alkermes to stop publishing Vivitrol ad

    1:12 p.m. Dec. 11, 2019

    - Jaimy Lee

  6. Alkermes to acquire Rodin Therapeutics for up to $950 million

    8:30 a.m. Nov. 18, 2019

    - Ciara Linnane

  7. Biogen shares fall 3%

    4:08 p.m. Nov. 14, 2019

    - Jaimy Lee

  8. Biogen, Alkermes MS treatment Vumerity gets FDA approval

    7:33 a.m. Oct. 30, 2019

    - Tomi Kilgore

  9. Alkermes upgraded to equal weight at Morgan Stanley

    10:09 a.m. Sept. 5, 2019

    - Tomi Kilgore

  10. Alkermes stock price target cut to $34 from $40 at Stifel Nicolaus

    8:55 a.m. Feb. 15, 2019

    - Tomi Kilgore

  11. Alkermes shares fall after FDA blocks antidepressant approval

    5:56 p.m. Feb. 1, 2019

    - Wallace Witkowski

  12. Alkermes reports positive results in late-stage trial of schizophrenia treatment

    8:01 a.m. Nov. 29, 2018

    - Ciara Linnane

  13. Alkermes halted premarket for news pending

    7:57 a.m. Nov. 29, 2018

    - Ciara Linnane

  14. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/alks

Other News on ALKS

  1. LGND or ALKS: Which Is the Better Value Stock Right Now?

    11:40 a.m. Today

    - Zacks.com

  2. Alkermes Plc (ALKS) Investor Presentation - Slideshow

    6:52 a.m. Sept. 22, 2020

    - Seeking Alpha

  3. Alkermes 4230 shows encouraging single-agent activity

    7:19 a.m. Sept. 18, 2020

    - Seeking Alpha

  4. Alkermes ALKS 4240 shows encouraging action in solid tumors

    7:19 a.m. Sept. 18, 2020

    - Seeking Alpha

  5. Seeking Alpha Catalyst Watch

    3:30 p.m. Sept. 11, 2020

    - Seeking Alpha

  6. Alkermes sues Teva to block generic version of Vivitrol

    7:29 a.m. Sept. 10, 2020

    - Seeking Alpha

  7. LGND or ALKS: Which Is the Better Value Stock Right Now?

    11:40 a.m. Sept. 9, 2020

    - Zacks.com

  8. ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

    11:40 a.m. Aug. 21, 2020

    - Zacks.com

  9. ANIK or ALKS: Which Is the Better Value Stock Right Now?

    11:40 a.m. Aug. 5, 2020

    - Zacks.com

  10. Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates

    11:08 a.m. July 30, 2020

    - Zacks.com

  11. Alkermes (ALKS) Receives a Hold from H.C. Wainwright

    8:35 a.m. July 30, 2020

    - SmarterAnalyst

  12. Alkermes plc 2020 Q2 - Results - Earnings Call Presentation

    9:31 a.m. July 29, 2020

    - Seeking Alpha

  13. Loading more headlines...
/news/pressrelease/company/us/alks

Press Releases on ALKS

  1. Injectable Drug Delivery Market Global Research and Clinical Survey Report 2020-2026

    4:14 a.m. Today

    - Market Insight Reports

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.